Form 8-K - Current report:
SEC Accession No. 0001493152-25-007898
Filing Date
2025-02-21
Accepted
2025-02-21 16:59:21
Documents
41
Period of Report
2025-02-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 4.01: Changes in Registrant's Certifying Accountant
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.05: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
Item 5.06: Change in Shell Company Status
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 257793
2 ex1-1.htm EX-1.1 71673
3 ex3-1.htm EX-3.1 5060
4 ex3-2.htm EX-3.2 166553
5 ex10-1.htm EX-10.1 351662
6 ex10-3.htm EX-10.3 203395
7 ex10-4.htm EX-10.4 46942
8 ex10-5.htm EX-10.5 127493
9 ex10-8.htm EX-10.8 24931
10 ex10-9.htm EX-10.9 69147
11 ex10-10.htm EX-10.10 81208
12 ex10-11.htm EX-10.11 96249
13 ex10-12.htm EX-10.12 97532
14 ex10-37.htm EX-10.37 174287
15 ex10-40.htm EX-10.40 192133
16 ex16-1.htm EX-16.1 1733
17 ex21-1.htm EX-21.1 1793
18 ex99-1.htm EX-99.1 166144
19 ex99-2.htm EX-99.2 7569
20 ex3-1_001.jpg GRAPHIC 156768
21 ex3-1_002.jpg GRAPHIC 311038
22 ex3-1_003.jpg GRAPHIC 565691
23 ex3-1_004.jpg GRAPHIC 486197
24 ex3-1_005.jpg GRAPHIC 527774
25 ex3-1_006.jpg GRAPHIC 368703
26 ex3-1_007.jpg GRAPHIC 82597
27 ex16-1_001.jpg GRAPHIC 142235
28 ex99-2_001.jpg GRAPHIC 23321
  Complete submission text file 0001493152-25-007898.txt   6470298

Data Files

Seq Description Document Type Size
29 XBRL SCHEMA FILE asbp-20250217.xsd EX-101.SCH 3831
30 XBRL DEFINITION FILE asbp-20250217_def.xml EX-101.DEF 28307
31 XBRL LABEL FILE asbp-20250217_lab.xml EX-101.LAB 37864
32 XBRL PRESENTATION FILE asbp-20250217_pre.xml EX-101.PRE 26519
43 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 7501
Mailing Address 1200 BROADWAY, FLOOR 3 NEW YORK NY 10038
Business Address 1200 BROADWAY, FLOOR 3 NEW YORK NY 10038 561-704-8527
Aspire Biopharma Holdings, Inc. (Filer) CIK: 0001847345 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41293 | Film No.: 25652847
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)